Text Size

Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye

Hagigit T., Abdulrazik M., Orucov F., Valamanesh F., Lambert M., Lambert G., Behar-Cohen F., Benita S.


  • 2010
  • Journal of Controlled Release
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Preclinical development

  • Affiliations

    Department of Pharmaceutics, The School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel; Department of Ophthalmology, Hadassah, Hebrew University Medical Center, Jerusalem, Israel; INSERM U598, Paris, France; Novagali, Evry, France; Rothschild Foundation, Paris, France

Related Publications

The growing burden of myopia in Europe: evidence from population-based cohorts

Tiemens A., van Hemert D.J., Lemma S.T., Quist S.W., Shi-van Wielink K., Agius D., Arnould L., Berendschot T.T.J.M., Beuse A., Bikbov M.M., Birtel J., Bountziouka V., Breteler M.M.B., Carbonaro F., Chakravarthy U., Coimbra R., de Vries V.A., Delcourt C., Farinha C., Finger R.P., Ghanbari M., Giannoulis D.A., Grohmann C., Hammond C.J., European Eye Epidemiology (E3) Consortium


Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes

Jovanović J., Zacharioudaki M., Kalatzi M., Papadakis G., Mulkalapalli N., Ernst F., de Milliano T.


Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022